Evidence map›Paper›PMID 24653978›Full record

ArticleFrontiers in oncology2014

Diffusion of Intraperitoneal Chemotherapy in Women with Advanced Ovarian Cancer in Community Settings 2003-2008: The Effect of the NCI Clinical Recommendation.

Erin J Aiello Bowles, Karen J Wernli, Heidi J Gray, Andy Bogart, Thomas Delate, Maureen O'Keeffe-Rosetti, Larissa Nekhlyudov, Elizabeth Trice Loggers

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
4.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Erin J Aiello BowlesGroup Health Research Institute, Group Health Cooperative , Seattle, WA , USA.
Karen J WernliGroup Health Research Institute, Group Health Cooperative , Seattle, WA , USA.
Heidi J GrayFred Hutchinson Cancer Research Center , Seattle, WA , USA ; University of Washington , Seattle, WA , USA.
Andy BogartGroup Health Research Institute, Group Health Cooperative , Seattle, WA , USA.
Thomas DelatePharmacy Department, Kaiser Permanente Colorado , Aurora, CO , USA.
Maureen O'Keeffe-RosettiCenter for Health Research, Kaiser Permanente Northwest , Portland, OR , USA.
Larissa NekhlyudovDepartment of Population Medicine, Harvard Medical School , Boston, MA , USA ; Department of Medicine, Harvard Vanguard Medical Associates , Boston, MA , USA.
Elizabeth Trice LoggersGroup Health Research Institute, Group Health Cooperative , Seattle, WA , USA ; Fred Hutchinson Cancer Research Center , Seattle, WA , USA ; University of Washington , Seattle, WA , USA.
Group Health Cooperative · USFred Hutch Cancer Center · USHarvard Vanguard Medical Associates · USKaiser Permanente · USKaiser Permanente Center for Health Research · US

Funding

The HMO Cancer Research Network (CRN)U19CA079689 · NCI · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI WAGNER, EDWARD H · 1999 to 2011
$62.6M
Medical Care Burden of Cancer: System and Data IssuesR01CA114204 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI HORNBROOK, MARK CHRISTOPHER · 2007 to 2010
$2.7M
AHRQ HHS K12 HS019482NCI NIH HHS R01 CA114204NCI NIH HHS U19 CA079689
6 · The paper itself

Abstract

purposeA 2006 National Cancer Institute clinical announcement recommended the use of combined intravenous (IV) and intraperitoneal (IP) chemotherapy over IV chemotherapy alone for women with International Federation of Gynecology and Obstetrics (FIGO) stage 3 optimally debulked ovarian cancer due to significant survival benefit demonstrated in multiple randomized clinical trials. We examined uptake of IP chemotherapy in community practice before and after this recommendation.

methodsWe identified 288 women with FIGO stage 2 or greater incident ovarian cancer diagnosed from 2003 to 2008 at three integrated delivery systems in the US. Administrative health plan data were used to determine patient characteristics and receipt of IV and IP chemotherapy within 12 months of diagnosis. We compared characteristics of women receiving IV chemotherapy alone vs. IP chemotherapy (with or without IV chemotherapy) and assessed temporal trends in IP chemotherapy use.

resultsOverall 12.5% (n = 36) of women received IP chemotherapy during the study period. IP chemotherapy use was non-existent between 2003 and 2005. Use of IP chemotherapy occurred among 26.9% of women diagnosed in 2006 and plateaued at 20.4% of women diagnosed in 2008. IP recipients were younger (mean age 55.9 vs. 63.5 years, p = < 0.001) and more likely to have stage 3 ovarian cancer (77.8 vs. 50.4% p = 0.039) compared to their IV-only chemotherapy counterparts.

conclusionUse of IP chemotherapy for newly diagnosed advanced stage ovarian cancer patients was uncommon in this community setting. Future research should identify potential patient, physician, and system barriers and facilitators to using IP chemotherapy in this setting.

Indexed as

agechemotherapydiffusionintraperitonealovarian cancerstage

Identifiers

PMID24653978
PMCPMC3948091
OpenAlexW2053221542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.